JP2023506598A - Pick1の脂質共役ペプチド阻害剤 - Google Patents

Pick1の脂質共役ペプチド阻害剤 Download PDF

Info

Publication number
JP2023506598A
JP2023506598A JP2022553063A JP2022553063A JP2023506598A JP 2023506598 A JP2023506598 A JP 2023506598A JP 2022553063 A JP2022553063 A JP 2022553063A JP 2022553063 A JP2022553063 A JP 2022553063A JP 2023506598 A JP2023506598 A JP 2023506598A
Authority
JP
Japan
Prior art keywords
pick1
peptide
npeg
inhibitor
hwlkv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022553063A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023506598A5 (cg-RX-API-DMAC7.html
Inventor
マドセン,ケネス,エル.
ゲザー,ウルリク
クリステンセン,ニコライ,リース
Original Assignee
ユニバーシティ オブ コペンハーゲン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティ オブ コペンハーゲン filed Critical ユニバーシティ オブ コペンハーゲン
Publication of JP2023506598A publication Critical patent/JP2023506598A/ja
Publication of JP2023506598A5 publication Critical patent/JP2023506598A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Detergent Compositions (AREA)
JP2022553063A 2020-03-06 2021-03-05 Pick1の脂質共役ペプチド阻害剤 Pending JP2023506598A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20161493 2020-03-06
EP20161493.0 2020-03-06
PCT/EP2021/055678 WO2021176094A1 (en) 2020-03-06 2021-03-05 Lipid conjugated peptide inhibitors of pick1

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026078179A Division JP2026129923A (ja) 2020-03-06 2026-05-07 Pick1の脂質共役ペプチド阻害剤

Publications (2)

Publication Number Publication Date
JP2023506598A true JP2023506598A (ja) 2023-02-16
JP2023506598A5 JP2023506598A5 (cg-RX-API-DMAC7.html) 2024-03-14

Family

ID=69780027

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022553063A Pending JP2023506598A (ja) 2020-03-06 2021-03-05 Pick1の脂質共役ペプチド阻害剤

Country Status (10)

Country Link
US (1) US20230346948A1 (cg-RX-API-DMAC7.html)
EP (1) EP4114524A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023506598A (cg-RX-API-DMAC7.html)
KR (1) KR20220150313A (cg-RX-API-DMAC7.html)
CN (1) CN115362001A (cg-RX-API-DMAC7.html)
AU (1) AU2021232645B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022017673A2 (cg-RX-API-DMAC7.html)
CA (1) CA3168324A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022011051A (cg-RX-API-DMAC7.html)
WO (1) WO2021176094A1 (cg-RX-API-DMAC7.html)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017501132A (ja) * 2013-12-01 2017-01-12 ユニバーシティ オブ コペンハーゲン Psd−95の二量体阻害剤脂肪酸誘導体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2111413A2 (en) * 2007-02-16 2009-10-28 Genetech, Inc. Htra1-pdz and htra3-pdz modulators
KR102046830B1 (ko) * 2011-05-13 2019-11-20 코벤하븐스 유니버시테트 허혈성 뇌 손상에 대한 효과적인 신경보호제이며 통증의 치료를 위한 psd-95의 고-친화성, 이량체 저해제
WO2020083905A1 (en) 2018-10-22 2020-04-30 University Of Copenhagen Inhibitors of pick1 and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017501132A (ja) * 2013-12-01 2017-01-12 ユニバーシティ オブ コペンハーゲン Psd−95の二量体阻害剤脂肪酸誘導体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NEUROPHARMACOLOGY, vol. 164, JPN6025013297, 2 December 2019 (2019-12-02), pages 107901 - 1, ISSN: 0005764983 *

Also Published As

Publication number Publication date
BR112022017673A2 (pt) 2022-11-08
AU2021232645B2 (en) 2026-07-09
WO2021176094A1 (en) 2021-09-10
US20230346948A1 (en) 2023-11-02
AU2021232645A1 (en) 2022-09-15
CA3168324A1 (en) 2021-09-10
KR20220150313A (ko) 2022-11-10
CN115362001A (zh) 2022-11-18
EP4114524A1 (en) 2023-01-11
MX2022011051A (es) 2022-12-15

Similar Documents

Publication Publication Date Title
CN110536680B (zh) 用于靶向活化cd44分子的树枝状聚合物纳米载体递送系统、其制备方法和用途
Lin et al. Hippocampal HDAC6 promotes POCD by regulating NLRP3-induced microglia pyroptosis via HSP90/HSP70 in aged mice
US20150314010A1 (en) Potentiation of anticancer agents
Ran et al. All-stage precisional glioma targeted therapy enabled by a well-designed D-peptide
AU2009304505A1 (en) Etoposide and doxorubicin conjugates for drug delivery
US12419839B2 (en) Methods and compositions for targeted delivery of protein fragments
JP6032854B2 (ja) 抗新生物及び抗血管新生活性を有する環状ペプチド
US12590130B2 (en) Bipartite molecules and uses thereof in treating diseases associated with abnormal protein aggregates
US20250090673A1 (en) Conjugate for targeting central nervous system
CA3086279A1 (en) Liposomes comprising sphingomyelin
JP6314135B2 (ja) in−vivoで神経変性疾患(特にアルツハイマー病)に活性なリポソーム
US20210347821A1 (en) Inhibitors of pick1 and uses thereof
JP2025527938A (ja) 脳透過性ペプチドおよびその使用方法
WO2023113843A2 (en) Borylated di-peptide amino acid compositions for use in boron neutron capture therapy and methods thereof
ES2247329T3 (es) Prevencion de muerte celular utilizando segmentos de proteinas fibrilares neurales.
Mun et al. Dual alarmin-receptor-specific targeting peptide systems for treatment of sepsis
US20230346948A1 (en) Lipid conjugated peptide inhibitors of PICK1
Chang et al. A newly designed molecule J2326 for Alzheimer's disease disaggregates amyloid fibrils and induces neurite outgrowth
Kandimalla et al. Physiological and biophysical factors that influence Alzheimer’s disease amyloid plaque targeting of native and putrescine modified human amyloid β40
AU2016364308B2 (en) Compound for use in the prevention and treatment of neurodegenerative diseases
JP7713129B1 (ja) 組成物
US12214076B2 (en) Drug delivery vehicles for atherosclerosis nanomedicine
Schlichtmann et al. Modified from a manuscript to be submitted to Advanced Healthcare Materials
Duarte Resveratrol and Grape's Extract-Loaded Solid Lipid Nanoparticles for the Treatment of Parkinson's and Alzheimer's Diseases
WO2015105957A1 (en) Pten antagonist peptides and methods of using the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240304

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250401

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250627

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250930

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260507